Suppr超能文献

利用排尿中的端粒酶活性诊断膀胱癌。

Diagnosis of bladder cancer using telomerase activity in voided urine.

作者信息

Cheng C W, Chueh S C, Chern H D

机构信息

Graduate Institute of Pharmaceutical Sciences, National Taiwan University, 1 Jen-Ai Road, Section 1, Taipei, Taiwan.

出版信息

J Formos Med Assoc. 2000 Dec;99(12):920-5.

Abstract

BACKGROUND AND PURPOSE

Telomerase is an essential enzyme for cellular immortality and tumorigenesis. Reactivation of telomerase is associated with many primary cancers. We evaluated the accuracy of a modified immunodiagnostic technique based on the telomeric repeat amplification protocol (TRAP) assay, by semi-quantitative measurement of telomerase activity in exfoliated urothelial cells in voided urine from patients with bladder cancer.

METHODS

Telomerase activity was assayed in centrifuged urine cell pellets from 17 bladder cancer patients and from 32 patients with benign bladder diseases. Each specimen was collected from a 50-mL sample of single voided urine obtained before surgery, and telomerase activity was detected using a telomerase polymerase chain reaction and enzyme-linked immunosorbent assay (PCR-ELISA) protocol. Results of pathologic study, urine cytologic examination, and urine telomerase activity were determined independently.

RESULTS

The cut-off value for relative telomerase activity was set at 0.059, which provided an optimal diagnostic accuracy of 88% (n = 49). At this cut-off value, the sensitivity and specificity for urine telomerase in bladder cancer were 82% (n = 17) and 91% (n = 32), respectively. Telomerase activity was found in 11 low-grade tumors and six high-grade tumors, whereas negative results for telomerase activity were found in urothelial cells of patients with inguinal hernia, urinary stones, acute urinary tract infection, or chronic cystitis. Only five cytology samples from the same patients were positive for bladder cancer. The difference in these two detection rates was significant (p = 0.002).

CONCLUSION

The results of this study indicate that the measurement of telomerase activity from voided urine using our modified semi-quantitative PCR-ELISA technique may help provide earlier diagnosis of bladder cancer and earlier postoperative indication of recurrence.

摘要

背景与目的

端粒酶是细胞永生化和肿瘤发生所必需的酶。端粒酶的重新激活与许多原发性癌症相关。我们通过对膀胱癌患者排尿中脱落的尿路上皮细胞中端粒酶活性进行半定量测量,评估了一种基于端粒重复序列扩增法(TRAP)检测的改良免疫诊断技术的准确性。

方法

对17例膀胱癌患者和32例膀胱良性疾病患者的离心尿细胞沉淀进行端粒酶活性检测。每个样本均取自术前采集的50毫升单次排尿样本,使用端粒酶聚合酶链反应和酶联免疫吸附测定(PCR-ELISA)方法检测端粒酶活性。病理研究、尿液细胞学检查和尿液端粒酶活性结果均独立测定。

结果

相对端粒酶活性的临界值设定为0.059,此时诊断准确性最佳,为88%(n = 49)。在此临界值下,膀胱癌患者尿液端粒酶的敏感性和特异性分别为82%(n = 17)和91%(n = 32)。在11例低级别肿瘤和6例高级别肿瘤中检测到端粒酶活性,而在腹股沟疝、尿路结石、急性尿路感染或慢性膀胱炎患者的尿路上皮细胞中未检测到端粒酶活性。同一患者中只有5份细胞学样本呈膀胱癌阳性。这两种检测率的差异具有统计学意义(p = 0.002)。

结论

本研究结果表明,使用我们改良的半定量PCR-ELISA技术测量排尿中的端粒酶活性,可能有助于早期诊断膀胱癌并早期提示术后复发。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验